Eli Lilly raises full-year sales forecast; Q3 revenue reaches $24.4 billion, exceeding expectations

Eli Lilly (LLY.US) announced its Q3 2026 financial results, raised its full-year sales guidance, and shared updates on the regulatory approval progress of its products. The company now expects full-year 2026 sales to reach $91-92 billion, up from the previous estimate of $85-87 billion. Due to acquisition impacts, the company forecasts full-year adjusted earnings per share of $35-36, slightly below the prior guidance range. Eli Lilly's Q3 revenue reached $24.4 billion, surpassing Wall Street analysts' average estimate of $22.5 billion. Sales of the diabetes drug Mounjaro totaled $10.7 billion, while the weight-loss drug Zepbound brought in $5.35 billion, both outperforming analysts' expectations. Eli Lilly shares rose over 4% in pre-market trading. As of Wednesday's close, the stock has risen nearly 20% so far this year.